US20010041733A1 - Heterocyclic ester and amide hair growth compositions and uses - Google Patents
Heterocyclic ester and amide hair growth compositions and uses Download PDFInfo
- Publication number
- US20010041733A1 US20010041733A1 US09/879,888 US87988801A US2001041733A1 US 20010041733 A1 US20010041733 A1 US 20010041733A1 US 87988801 A US87988801 A US 87988801A US 2001041733 A1 US2001041733 A1 US 2001041733A1
- Authority
- US
- United States
- Prior art keywords
- straight
- branched chain
- group
- chain alkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *N(C(~[W])C(C)~[Y])C(B)C(=*)*C Chemical compound *N(C(~[W])C(C)~[Y])C(B)C(=*)*C 0.000 description 15
- RYERBUYGMXELAQ-QGZVFWFLSA-N CCC(C)(C)C(=O)C(=O)N1CCS[C@@H]1C(=O)OCCCC1=CN=CC=C1 Chemical compound CCC(C)(C)C(=O)C(=O)N1CCS[C@@H]1C(=O)OCCCC1=CN=CC=C1 RYERBUYGMXELAQ-QGZVFWFLSA-N 0.000 description 2
- VVFVHRQMJTWSAK-DEOSSOPVSA-N CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)SCCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)SCCC(C1=CC=CC=C1)C1=CC=CC=C1 VVFVHRQMJTWSAK-DEOSSOPVSA-N 0.000 description 1
- DMSCXFUGACMGTF-KRWDZBQOSA-N CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)CCCCC1=CN=CC=C1 Chemical compound CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)CCCCC1=CN=CC=C1 DMSCXFUGACMGTF-KRWDZBQOSA-N 0.000 description 1
- OQAHHWOPVDDWHD-INIZCTEOSA-N CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCC1=CN=CC=C1 Chemical compound CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCC1=CN=CC=C1 OQAHHWOPVDDWHD-INIZCTEOSA-N 0.000 description 1
- APNOXCGIEGKCFC-QHCPKHFHSA-N CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)SCCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)SCCC(C1=CC=CC=C1)C1=CC=CC=C1 APNOXCGIEGKCFC-QHCPKHFHSA-N 0.000 description 1
- SDGJNXLBKNQUGU-UQQXROCHSA-N O=C(SCCCC1=CC=CC=C1)[C@@H]1CCCN1C(=O)NC12CC3CC(CC(C3)C1)C2 Chemical compound O=C(SCCCC1=CC=CC=C1)[C@@H]1CCCN1C(=O)NC12CC3CC(CC(C3)C1)C2 SDGJNXLBKNQUGU-UQQXROCHSA-N 0.000 description 1
- USWRBKQWZNIPKB-FQEVSTJZSA-N O=C(SCCCC1=CC=CC=C1)[C@@H]1CCCN1S(=O)(=O)CC1=CC=CC=C1 Chemical compound O=C(SCCCC1=CC=CC=C1)[C@@H]1CCCN1S(=O)(=O)CC1=CC=CC=C1 USWRBKQWZNIPKB-FQEVSTJZSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Definitions
- This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, small molecular heterocyclic esters or amides.
- Hair loss occurs in a variety of situations. These situations include male pattern alopecia, alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and hair loss are very complicated, but in some instances can he attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities.
- the immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner.
- alopecia areata One form of hair loss, alopecia areata, is known to be associated with autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss.
- the hair growth stimulating effects of FK506 have been the subject of an international patent filing covering stimulation (Honbo et al., EP 0 423 714 A2).
- Honbo et al. discloses the use of relatively large tricyclic compounds, known for the immunosuppressive effects, as hair revitalizing agents.
- immunosuppressive compounds by definition suppress the immune system and also exhibit other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds.
- the present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.
- the present invention further relates to a pharmaceutical composition which comprises:
- heterocyclic esters and amides used in the inventive methods and pharmaceutical compositions have an affinity for FKBP-type immunophilins and do not exert any significant immunosuppressive activity.
- FIG. 1 is a photogragh of C57 Black 6 mice before being shaved for the hair regeneration experiment.
- FIG. 2 is a photograph of mice treated with a vehicle a six weeks.
- FIG. 2 shows that less than 3% of the shaved area is covered with new hair growth when the vehicle (control) is administered.
- FIG. 3 is a photograph of mice treated with 10 ⁇ M of GPI 1046, a related non-immunosuppressive neuroimmunophilin FKBP ligand, after six weeks.
- FIG. 3 shows the remarkable effects of neuroimmunophilin FKBP ligands, wherein 90% of the shaved area is covered with new hair growth.
- FIG. 4 is a photograph of mice treated with 30 ⁇ M of GPI 1046, a related non-immunosuppressive neuroimmunophilin FKBP ligand, after six weeks.
- FIG. 4 shows the remarkable ability of neuroimmunophilin FKBP ligands to achieve, essentially, complete hair regrowth in the shaved area.
- FIG. 5 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and various non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572, 14 days after treatment with each identified compound.
- FIG. 5 demonstrates the remarkable early hair growth neuroimmunophilin FKBP ligands.
- Alopecia refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness) , toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania.
- Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen chase during which the follicles are detached from the dermal papillae, and the hairs fall out.
- Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs.
- GPI 1046 refers to 3-(3-pyridyl)-1-propyl (2s-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidine-carboxylate, a compound of formula
- “Isomers” refer to different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space, “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. “Diastereoisomers” are stereoisomers which are not mirror images of each other. “Racemic mixture” means a mixture containing equal parts of individual enantiomers. “Non-racemic mixture” is a mixture containing unequal parts or individual enantiomers or stereoisomers.
- “Pharmaceutically acceptable salt, ester, or solvate” refers to a salt, ester, or solvate or a subject compound which possesses the desired pharmacolocical activity and which is neither biologically nor otherwise undesirable.
- a salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanes
- base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth.
- the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long stearyl chlorides, bromides, and iodides; aralkyl halides such as benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides
- dialkyl sulfates such as dimethyl, diethyl, dibutyl, and diamyl sulfates
- long stearyl chlorides, bromides, and iodides long stearyl
- Palm cycle refers to the life cycle of hair follicles, and includes three phases:
- telogen phase hair is uniform in diameter with a slightly bulbous, non-pigmented root.
- anagen phase hair has a large colored bulb at its root.
- “Promoting hair growth” refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
- Treating alopecia refers to:
- Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep in the dermis.
- Vellus hair is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type.
- the present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.
- the inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising:
- the heterocyclic esters and amides used in the methods and pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for an FKBP-type immunophilin, such as FKBP12.
- FKBP-type immunophilin such as FKBP12.
- FKBP12 FKBP12
- a heterocyclic ester or amide binds to an FKBP-type immunophilin, it has been found to inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein. Unexpectedly, the compounds have also been found to stimulate hair growth. The compounds are devoid of any significant immunosuppressive activity.
- the heterocyclic ester or amide may be a compound of formula I
- a and B together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO 2 , N, NH or NR 1 heteroatom(s);
- X is O or S
- Z is O, NH or NR
- W and Y are independently O, S, CH 2 , or H2;
- R 1 is C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkyl, which is substituted with one or more sustituent(s) independently selected from the group consisting of (Ar 1 ) n , C 3 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl substituted with (Ar 1 ) n , C 3 -C 9 cycloalkyl, C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 , straight or branched chain alkenyl substituted with C 3 -C 8 cycloalkyl, and Ar 2 ;
- n 1 or 2;
- R 2 is either C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain or alkenyl, C 3 -C 9 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 1 , wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C 1 -C 4 straight or branched chain alkyl, C 2 -C 4 straight or branched chain alkenyl, and hydroxyl; and
- Ar 1 and Ar 2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6members; and wherein the heterocyclic ring contains 7-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
- Suitable carbo- and heterocyclic rings include without limitation naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl and phenyl.
- heterocyclic ester or amide may be a compound of formula II
- A, B and C are independently CH 2 , O, S, SO, SO 2 , NH or NR 1 ;
- R 1 is C 1 -C 5 straight or branched chain alkyl or C 2 -C 5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar 1 ) n and C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl substituted with (Ar 1 ) n ;
- n 1 or 2;
- R 2 is either C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 1 -C 9 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 1 ;
- Ar 1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C 1 -C 4 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
- the heterocyclic ester or amide is the compound GPI 1572, of the formula
- A is CH 2 ;
- B is CH 2 or S
- C is CH 2 or NH
- R 1 is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl;
- R 2 is selected from the group consisting of 1,1-dimethylpropyl cyclohexl, and tert-butyl.
- heterocyclic ester or amide may also be a compound of formula III
- A, B, C and D are independently CH 2 , O, S, SO, SO 2 , NH or NR 1 ;
- R 1 is C 1 -C 5 straight or branched chain alkyl or C 2 -C 5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar 1 ) n and C 1 -C 6 straight or branched chain alkyl or C 2 -C 6 straight or branched chain alkenyl substituted with (Ar 1 ) n ;
- n 1 or 2;
- R 2 is either C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 9 . cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 1 ; and
- Ar 1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
- A is CH 2 ;
- B is CH 2 ;
- C is S, O, or NH
- D is CH 2 ;
- R 1 is selected from the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl;
- R 2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5-trimethoxyphenyl.
- heterocyclic ester or amide may also be a compound of formula IV
- V is C, N, or S
- a and B taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO 2 , N, NH;, and N;
- R is either C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 1 -C 9 cycloalkyl, C 5 -C 7 cycloalkenyl, or Ar 3 , wherein R is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C 1 -C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, C 1 -C 4 alkoxy, C 1 -C 4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar 4 ;
- Ar 3 and Ar 4 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and
- R 1 , R 2 , W, X, Y, and Z are as defined in Formula I above.
- All the compounds of Formulas I-IV posses asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers.
- the individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving t he compounds of Formulas I-IV.
- the compounds of Formulas I-IV encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers.
- S-stereoisomers are used in the pharmaceutical compositions and methods of the present invention.
- the compounds used in the inventive methods and pharmaceutical compositions have an affinity for the inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.
- a plastic cuvette In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH: 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 mL of substrate in 2.35 mM LiCl in trifluoroethanol).
- the compounds used in the inventive methods and pharmaceutical compositions must readily affect the targeted areas.
- the compounds are preferably administered topically to the skin.
- the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- Dosage levels on the order of about 0.mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg.
- the specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.
- in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
- the compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the drug combination.
- Example 2 The compound of Example 2 was prepared according to the procedure of Example 1, using 3-(3-pyridyl)-1-propanol in the final step, to yield 3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate.
- Experiment A C57 black 6 mice were used to demonstrate the hair revitalizing properties of a low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligand, GPT 1046, which is related to heterocyclic esters and amides.
- GPT 1046 non-immunosuppressive neuroimmunophilin FKBP ligand, GPT 1046, which is related to heterocyclic esters and amides.
- FIGS. 1 and 2 of the drawings C57 black 6 mice, approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlaying dermal layers. The animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS.
- FIG. 2 shows that animals treated with vehicle exhibited only a small amount of hair growth in patches or tufts, with less than 3% of the shaved area covered with new growth.
- FIG. 3 shows dramatic hair growth, covering greater than 90% of the shaved area in all animals.
- FIG. 4 shows that mice treated with 30 ⁇ M GPI 1046 exhibited essentially complete hair regrowth and their shaved areas were indistinguishable from unshaven C57 black 6 mice.
- Experiment B C57 black 6 mice were used to demonstrate the hair revitalizing properties of a variety of low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572.
- CS57 Black 6 mice 55 to 75 days old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlying dermal layers. The animals were in a anagen growth phase when shaved.
- mice per group Five animals per group were treated by topical administration with vehicle, FK506, or one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FK506 ligands (GPI1605, 1046, 1312, 1572, 1389, 1511, and 1234) at a concentration of one micromole per milliliter to the shaved area.
- the animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area).
- FIG. 5 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572, exhibited dramatic hair growth.
- a lotion comprising the following composition may be prepared. (%) 95% Ethanol 80.0 a heterocyclic ester or amide as defined 10.0 above ⁇ -Tocopherol acetate 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s.
- 5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
- a lotion comprising the following composition shown may be prepared. (%) 95% Ethanol 80.0 a heterocyclic ester or amide as defined 0.005 above Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil Purified water 19.0 Perfume and dye q.s.
- the lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
- An emulsion may be prepared from A phase and B phase having the following compositions. (%) (A phase) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monocleate 1.0 a heterocyclic ester or amide as defined 0.01 above (B phase) Glycerine 10.0 Purified water 69.0 Perfume, dye, and preservative q.s.
- the A phase and the B phase are respectively heated and melted and maintained at 80° C. Both phased are then mixed and cooled under stirring to normal temperature to obtain an emulsion.
- the emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia.
- a cream may be prepared from A phase and B phase having the following compositions.
- (%) (A Phase) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3
- B Phase a heterocyclic ester or amide as defined 0.8 above Glycerine 7.0
- Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0.005 Purified water 44.895
- the A phase is heated and melted, and maintained at 70° C.
- the B phase is added into the A phase and the mixture is stirred to obtain an emulsion.
- the emulsion is then cooled to obtain a cream.
- the cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
- a liquid comprising the following composition may be prepared. (%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 a heterocyclic ester or amide as defined 0.001 above Propylene glycol 5.0 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q.s.
- the liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
- a shampoo comprising the following composition may be prepared. (%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 Polyethylene glycol 5.0 a heterocyclic ester or amide as defined 5.0 above Ethanol 2.0 Perfume 0.3 Purified water 69.7
- the shampoo may be used on the scalp once or twice per day.
- a patient is suffering from alopecia senilis.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from male pattern alopecia.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from alopecia areata.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by skin lesions.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by tumors.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by a systematic disorder, such as a nutritional disorder or an internal secretion disorder.
- a systematic disorder such as a nutritional disorder or an internal secretion disorder.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by chemotherapy.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- a patient is suffering from hair loss caused by radiation.
- a heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
Abstract
This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic esters or amides.
Description
- This application is a continuation-in-part of U.S. patent application No. 08/869,426, filed on Jun. 4, 1997, the entire contents of which are herein incorporated by reference.
- 1. Field of Invention
- This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, small molecular heterocyclic esters or amides.
- 2. Description of Related Art
- Hair loss occurs in a variety of situations. These situations include male pattern alopecia, alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and hair loss are very complicated, but in some instances can he attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities.
- The immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner. One form of hair loss, alopecia areata, is known to be associated with autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss. The hair growth stimulating effects of FK506 have been the subject of an international patent filing covering stimulation (Honbo et al.,
EP 0 423 714 A2). Honbo et al. discloses the use of relatively large tricyclic compounds, known for the immunosuppressive effects, as hair revitalizing agents. - The hair growth and revitalization effects of FK506 and related agents are disclosed in many U.S. patents (Goulet et al., U.S. Pat. No. 5,258,389; Luly et al., U.S. Pat. No. 5,457,111; Goulet et al., U.S. Pat. No. 5,532,248; Goulet et al., U.S. Pat. No. 5,189,042; and Ok et a U.S. Pat. No. 5,208,241; Rupprecht et al. U.S. Pat. No. 5,284,840; Organ et al., U.S. Pat. No. 5,284,877). These patents claim FK506 related compounds. Although they do not claim methods of hair revitalization, they disclose the known use of FK506 for effecting hair growth. Similar to FK506 (and the claimed variations in the Honbo et al. patent), the compounds claimed in these patents are relatively large. Further, the cited patents relate to immunomodulatory compounds for use in autoimmune related diseases, for which FK506's efficacy is well known.
- Other U.S. patents disclose the use of cyclosporin and related compounds for hair revitalization (Hauer et al., U.S. Pat. No. 5,342,625; Eberle, U.S. Pat. No. 5,284,826; Hewitt et al., U.S. Pat. No. 4,996,193). These patents also relate to compounds useful treating autoimmune diseases and cite the known use of cyclosporin and related immunosuppressive compounds for hair growth.
- However, immunosuppressive compounds by definition suppress the immune system and also exhibit other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds.
- Hamilton and Steiner disclose in U.S. Pat. No. 5,614,547 novel pyrrolidine carboxylate compounds which bind to the immunophilin FKBP12 and stimulate nerve growth, but which lack immunosuppressive effects. Unexpectedly, it has been discovered that these non-immunosuppressant compounds promote hair growth with an efficacy similar to FK506. Yet their novel small molecule structure and non-immunosuppressive properties differentiate them from FK506 and related immunosuppressive compounds found in the prior art.
- The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.
- The present invention further relates to a pharmaceutical composition which comprises:
- (i) an effective amount of a heterocyclic ester or amide for treating alopecia or promoting hair growth in an animal; and
- (ii) a pharmaceutically acceptable carrier.
- The heterocyclic esters and amides used in the inventive methods and pharmaceutical compositions have an affinity for FKBP-type immunophilins and do not exert any significant immunosuppressive activity.
- FIG. 1 is a photogragh of C57 Black 6 mice before being shaved for the hair regeneration experiment.
- FIG. 2 is a photograph of mice treated with a vehicle a six weeks. FIG. 2 shows that less than 3% of the shaved area is covered with new hair growth when the vehicle (control) is administered.
- FIG. 3 is a photograph of mice treated with 10 μM of GPI 1046, a related non-immunosuppressive neuroimmunophilin FKBP ligand, after six weeks. FIG. 3 shows the remarkable effects of neuroimmunophilin FKBP ligands, wherein 90% of the shaved area is covered with new hair growth.
- FIG. 4 is a photograph of mice treated with 30 μM of GPI 1046, a related non-immunosuppressive neuroimmunophilin FKBP ligand, after six weeks. FIG. 4 shows the remarkable ability of neuroimmunophilin FKBP ligands to achieve, essentially, complete hair regrowth in the shaved area.
- FIG. 5 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and various non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572, 14 days after treatment with each identified compound. FIG. 5 demonstrates the remarkable early hair growth neuroimmunophilin FKBP ligands.
- “Alopecia” refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness) , toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania. Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen chase during which the follicles are detached from the dermal papillae, and the hairs fall out. Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs.
-
-
-
-
-
-
-
- “Isomers” refer to different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space, “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. “Diastereoisomers” are stereoisomers which are not mirror images of each other. “Racemic mixture” means a mixture containing equal parts of individual enantiomers. “Non-racemic mixture” is a mixture containing unequal parts or individual enantiomers or stereoisomers.
- “Pharmaceutically acceptable salt, ester, or solvate” refers to a salt, ester, or solvate or a subject compound which possesses the desired pharmacolocical activity and which is neither biologically nor otherwise undesirable. A salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, naphthylate, 2-naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate and undecanoate. Examples of base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long stearyl chlorides, bromides, and iodides; aralkyl halides such as benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
- “Pilar cycle” refers to the life cycle of hair follicles, and includes three phases:
- (1) the anagen phase, the period of active hair growth which, insofar as scalp hair is concerned, lasts about three to five years;
- (2) the catagen phase, the period when growth stops and the follicle atrophies which, insofar as scalp hair is concerned, lasts about one to two weeks; and
- (3) the telogen phase, the rest period when hair progressively separates and finally falls out: which, insofar as scalp hair is concerned, lasts about three to four months.
- Normally 80 to 90 percent of the follicles are in the anagen phase, less than 1 percent being in the catagen phase, and the rest being in the telogen phase. In the telogen phase, hair is uniform in diameter with a slightly bulbous, non-pigmented root. By contrast, in the anagen phase, hair has a large colored bulb at its root.
- “Promoting hair growth” refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
- “Treating alopecia” refers to:
- (i) preventing alopecia in an animal which may be predisposed to alopecia; and/or
- (ii) inhibiting, retarding or reducing alopecia; and/or
- (iii) promoting hair growth; and/or
- (iv) prolonging the anagen phase of the hair cycle; and/or
- (v) converting vellus hair to growth as terminal hair. Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep in the dermis. Vellus hair, on the other hand, is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type.
- The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.
- The inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
- Pharmaceutical Compositions of the Present Invention
- The present invention also relates to a pharmaceutical composition comprising:
- (i) an effective amount of a heterocyclic ester or amide for treating alopecia or promoting hair growth in an animal; and
- (ii) a pharmaceutically acceptable carrier.
- The heterocyclic esters and amides used in the methods and pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for an FKBP-type immunophilin, such as FKBP12. When a heterocyclic ester or amide binds to an FKBP-type immunophilin, it has been found to inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein. Unexpectedly, the compounds have also been found to stimulate hair growth. The compounds are devoid of any significant immunosuppressive activity.
-
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- A and B, together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO2, N, NH or NR1 heteroatom(s);
- X is O or S;
- Z is O, NH or NR;
- W and Y are independently O, S, CH2, or H2;
- R1 is C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkyl, which is substituted with one or more sustituent(s) independently selected from the group consisting of (Ar1)n, C3-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n, C3-C9 cycloalkyl, C1-C6 straight or branched chain alkyl or C2-C6 , straight or branched chain alkenyl substituted with C3-C8 cycloalkyl, and Ar2;
- n is 1 or 2;
- R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain or alkenyl, C3-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar1, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C1-C4 straight or branched chain alkyl, C2-C4 straight or branched chain alkenyl, and hydroxyl; and
- Ar1 and Ar2 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6members; and wherein the heterocyclic ring contains 7-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
- Suitable carbo- and heterocyclic rings include without limitation naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl and phenyl.
-
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- A, B and C are independently CH2, O, S, SO, SO2, NH or NR1;
- R1 is C1-C5 straight or branched chain alkyl or C2-C5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n and C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
- n is 1 or 2;
- R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C1-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar1; and
- Ar1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C1-C4 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
-
- In a particularly preferred embodiment of formula compounds:
- A is CH2;
- B is CH2 or S;
- C is CH2 or NH;
- R1 is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl; and
- R2 is selected from the group consisting of 1,1-dimethylpropyl cyclohexl, and tert-butyl.
- Specific examples of this embodiment are presented in TABLE I.
TABLE I No. A B C R1 R2 1 CH2 S CH2 3-phenylpropyl 1,1- dimethylpropyl 2 CH2 S CH2 3-(3-pyridyl)propyl 1,1- dimethylpropyl 3 CH2 S CH2 3- phenylpropyl cyclohexyl 4 CH2 S CH2 3-phenylpropyl tert-butyl 5 CH2 CH2 NH 3-phenylpropyl 1,1-dimethylpropyl 6 CH2 CH2 NH 3-phenylpropyl cyclohexyl 7 CH2 CH2 NH 3-phenylpropyl tert-butyl -
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- A, B, C and D are independently CH2, O, S, SO, SO2, NH or NR1;
- R1 is C1-C5 straight or branched chain alkyl or C2-C5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n and C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
- n is 1 or 2;
- R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 . cycloalkyl, C5-C7 cycloalkenyl, or Ar1; and
- Ar1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxyl, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
- In a particularly preferred embodiment of formula III compounds:
- A is CH2;
- B is CH2;
- C is S, O, or NH;
- D is CH2;
- R1 is selected from the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl; and
- R2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5-trimethoxyphenyl.
- Specific examples of this embodiment are presented in TABLE II.
TABLE II No. A B C D R1 R2 8 CH2 CH2 S CH2 3-phenylpropyl 1,1-dimethylpropyl 9 CH2 CH2 O CH2 3-phenylpropyl 1,1-dimethylpropyl 10 CH2 CH2 S CH2 3-phenylpropyl cyclohexyl 11 CH2 CH2 O CH2 3-phenylpropyl cyclohexyl 12 CH2 CH2 S CH2 3-phenylpropyl phenyl 13 CH2 CH2 O CH2 3-phenylpropyl phenyl 14 CH2 CH2 NH CH2 3-phenylpropyl 1,1-dimethylpropyl 15 CH2 CH2 NH CH2 3-phenylpropyl phenyl -
- or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
- V is C, N, or S;
- A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH;, and N;
- R is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C1-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar3, wherein R is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C1-C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar4;
- Ar3 and Ar4 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and
- R1, R2, W, X, Y, and Z are as defined in Formula I above.
- All the compounds of Formulas I-IV posses asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving t he compounds of Formulas I-IV. It is understood that the compounds of Formulas I-IV encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers. Preferably, S-stereoisomers are used in the pharmaceutical compositions and methods of the present invention.
- The compounds used in the inventive methods and pharmaceutical compositions have an affinity for the inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.
- Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the compounds used in the inventive methods and pharmaceutical compositions can be evaluated by known methods described in the literature (Harding et al.,Nature, 1939, 341:758-760; Holt et al. J. Am. Chem. Soc., 115:9923-9938). These values are obtained as apparent K1's and are presented for representative compounds in TABLE III.
- The cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparerent K1, values.
- In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH: 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 mL of substrate in 2.35 mM LiCl in trifluoroethanol).
- The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.
TABLE III In Vitro Test Results - Formulas I to IV Compound Ki (nM) 1 215 2 638 - To effectively treat alopecia or promote hair growth, the compounds used in the inventive methods and pharmaceutical compositions must readily affect the targeted areas. For these purposes, the compounds are preferably administered topically to the skin.
- For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- Other routes of administration known in the pharmaceutical art are also contemplated by this invention.
- Dosage levels on the order of about 0.mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
- The compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the drug combination.
- The following example are illustrations of the present invention and are not intended to be limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition.
- A solution of L-thioproline (1.51 g; 11.34 mmol) in 40 mL of dry methylene chloride was cooled to 0° C. and treated with 3.3 mL (2.41 g; 23,81 mmol) of triethylamine. After stirring this mixture for 30 minutes, a solution of methyl oxalyl chloride (1.81 g; 14.74 mmol) was added dropwise. The resulting mixture was stirred at 0° C. for 1.5 hours, filtered through Celite to remove solids, dried and concentrated. The crude material was purified on a silic gel column, 2.0 g of this oxamate as ar. orange-yellow solid.
- 1-(1,2,-dioxo-2-methoxyethyl)2-(4-thiazolidine)-carboxylate (500 mg; 2.25 mmol) 3-phenyl-1-propanol 3.65 mmol), 4-dimethylaminopyridine (95 mg; 0.75 mmol) and camphorsulfonic: acid (175 mg; 0.75 mmol) in 30 mL of methylene chloride were stirred together overnight. The mixture was filtered through Celite to remove solids and chromatographed (25% ethyl acetate/hexane) to obtain 690 mg of material.1H NMR (CDCl3, 300 MHz); δ1.92-2.01 (m, 2H)); 2.61-2.69 (m, 2H); 3.34 (m, 1H) 4.11-4.25 (m, 2H) ; 4.73 (m, 1H) ; 5.34 (m1H); 7.12 (m, 3H) ; 7.23 (m, 2H).
- A solution of 3-phenyl-1-propyl(2S)-1-(1,2-dioxo-2-methoxyethyl)2-(4-thiazolidine)carboxylate (670 mg; 1.98 mmol) in tetrahydrofuran (10 mL) was cooled to—78° C. and treated with 2.3 mL of a 1.0 M solution of 1.1-dimethylpropylmagnesium chloride in ether. After stirring the mixture for 3 hours, it was poured into saturated ammonium chloride, extracted into ethyl acetate, and the organic phase was washed with water, dried and concentrated. The crude material was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 380 mg of the compound of Example 1 as a yellow oil.1H NMR (CDCl3, 300 MHz): d 0.86 (t, 3H); 1.21 (s, 3H); 1.26 (s, 3H); 1.62-1.91 (m, 3H); 2.01 (m, 2H); 2.71 (m, 2H); 3.26-3.33 (m, 2H) 4.19 (m 2H); 4.58 (m, 1H); 7.190 (m, 3H); 7.30 (m, 2H). Analysis calculated for C20H27NO4S:C C, 63.63; H, 7.23 N, 3.71. Found: C, 64.29; H, 7.39; N, 3.46.
- The compound of Example 2 was prepared according to the procedure of Example 1, using 3-(3-pyridyl)-1-propanol in the final step, to yield 3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate.1H NMR (CDCl3, 300 MHz): δ 0.89 (t, 3H, J=7.3); 1.25 (s, 3H); 1.28 (s, 3H); 1.77 (q, 2H, J=7.3); 2.03 (tt, 2H, J=6.4, 7.5); 2.72 (t, 2H, J=7.5); 3.20 (dd, 1H, J=4.0, 11.8); 3.23 (dd, 1H, J=7.0, 11.8); 4.23 (t, 2H, J=6.4); 4.55 (d, 2H, J=8.9); 5.08 (dd, 1H, J=4.0, 7.0); 7.24 (m, 1H); 8.48 (m, 2H). Analysis calculated for C19H26N2O4S—0.5H2O: C, 58.89; H, 7.02; N, 7.23. Found: C, 58.83; H, 7.05; N, 7.19.
- Experiment A: C57 black 6 mice were used to demonstrate the hair revitalizing properties of a low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligand, GPT 1046, which is related to heterocyclic esters and amides. Referring now to FIGS. 1 and 2 of the drawings, C57 black 6 mice, approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlaying dermal layers. The animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS. 2, 3 and4, four animals per group were treated by topical administration with 20% propylene glycol vehicle (FIG. 2), 10 μM GPI 1046 (FIG. 3) or 30 μM GPI 1046 (FIG. 4) dissolved in the vehicle. The animals were treated with vehicle or GPI 1046 every 48 hours (3 applications total over the course of 5 days) and the hair growth was allowed to proceed for 6 weeks. Hair growth was quantitated by the percent of shaved area covered by new hair growth during this time period.
- FIG. 2 shows that animals treated with vehicle exhibited only a small amount of hair growth in patches or tufts, with less than 3% of the shaved area covered with new growth. In contrast, FIG. 3 shows dramatic hair growth, covering greater than 90% of the shaved area in all animals. Further, FIG. 4 shows that mice treated with 30 μM GPI 1046 exhibited essentially complete hair regrowth and their shaved areas were indistinguishable from unshaven C57 black 6 mice.
- Experiment B: C57 black 6 mice were used to demonstrate the hair revitalizing properties of a variety of low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572. CS57 Black 6 mice, 55 to 75 days old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlying dermal layers. The animals were in a anagen growth phase when shaved. Five animals per group were treated by topical administration with vehicle, FK506, or one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FK506 ligands (GPI1605, 1046, 1312, 1572, 1389, 1511, and 1234) at a concentration of one micromole per milliliter to the shaved area. The animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area).
- FIG. 5 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands, including GPI 1572, exhibited dramatic hair growth.
- A lotion comprising the following composition may be prepared.
(%) 95% Ethanol 80.0 a heterocyclic ester or amide as defined 10.0 above α-Tocopherol acetate 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s. - Into 95% ethanol are added a heterocyclic ester or amide, α-tocopherol acetate, ethylene oxide (40 mole) adducts of hardened castor oil, perfume and a dye. The resulting mixture is stirred and dissolved, and purified water is added to the mixture to obtain a transparent liquid lotion.
- 5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
- A lotion comprising the following composition shown may be prepared.
(%) 95% Ethanol 80.0 a heterocyclic ester or amide as defined 0.005 above Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil Purified water 19.0 Perfume and dye q.s. - Into 95% ethanol are added a heterocyclic ester or amide, hinokitol, ethylene oxide (40 mole) adducts of hardened castor oil, perfume, and a dye. The resulting mixture is stirred, and purified water is added to the mixture to obtain a transparent liquid lotion.
- The lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
- An emulsion may be prepared from A phase and B phase having the following compositions.
(%) (A phase) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monocleate 1.0 a heterocyclic ester or amide as defined 0.01 above (B phase) Glycerine 10.0 Purified water 69.0 Perfume, dye, and preservative q.s. - The A phase and the B phase are respectively heated and melted and maintained at 80° C. Both phased are then mixed and cooled under stirring to normal temperature to obtain an emulsion.
- The emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia.
- A cream may be prepared from A phase and B phase having the following compositions.
(%) (A Phase) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3 (B Phase) a heterocyclic ester or amide as defined 0.8 above Glycerine 7.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0.005 Purified water 44.895 - The A phase is heated and melted, and maintained at 70° C. The B phase is added into the A phase and the mixture is stirred to obtain an emulsion. The emulsion is then cooled to obtain a cream.
- The cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
- A liquid comprising the following composition may be prepared.
(%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 a heterocyclic ester or amide as defined 0.001 above Propylene glycol 5.0 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q.s. - Into ethanol are added polyoxypropylene butyl ether, propylene glycol, polyoxyethylene hardened castor oil, a heterocyclic ester or amide, and perfume. The resulting mixture is stirred, and purified water is added to the mixture to obtain a liquid.
- The liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
- A shampoo comprising the following composition may be prepared.
(%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 Polyethylene glycol 5.0 a heterocyclic ester or amide as defined 5.0 above Ethanol 2.0 Perfume 0.3 Purified water 69.7 - Into 69.7 of purified water are added 5.0 g of sodium laurylsulfate, 5.0 g triethanolamine laurylsulfate, 6.0 g of betaine lauryldimethyl-aminoacetate. Then a mixture obtained by adding 5.0 g of a heterocyclic ester or amide, 5.0 g of polyethylene glycol, and 2.0 g of ethylene glycol distearate to 2.0 g of ethanol, followed by stirring, and 0.3 g of perfume are successively added. The resulting mixture is heated and subsequently cooled to obtain a shampoo.
- The shampoo may be used on the scalp once or twice per day.
- A patient is suffering from alopecia senilis. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from male pattern alopecia. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from alopecia areata. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by skin lesions. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by tumors. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by a systematic disorder, such as a nutritional disorder or an internal secretion disorder. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by chemotherapy. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- A patient is suffering from hair loss caused by radiation. A heterocyclic ester or amide as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
- The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.
Claims (32)
1. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.
2. The method of , wherein the heterocyclic ester or amide is non-immunosuppressive.
claim 1
3. The method Of , wherein the heterocyclic ester or amide has an affinity for an FKBP-type immunophilin.
claim 1
4. The method of , wherein the FKBP-type immunophilin if FKBP-12.
claim 3
5. The method of , wherein the heterocyclic ester or amide is a compound of formula I
claim 1
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, together with the nitrogen and carbon atoms to which they are respectively attacked, form a 5 -7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO1, N, NH, or NR1heteroatom;
X is O or S;
Z is O, NH, or NR1;
W and Y are independently O, S, CH2, or H2;
R1 is C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n, C3-C9 cycloalkyl, straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with C3-C8 cycloalkyl, and Ar2;
n is 1 or 2;
R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C9-C7 cycloalkenyl or Ar1, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C1-C4 straight or branched chain alkyl, C2-C4 straight or branched chain alkenyl, and hydroxy; and
Ar1 and Ar2 are independently an alicyclic or aromatic, mono-, bi or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
6. The method of , wherein the mono- or bicyclic, carbo- or heterocyclic ring is selected from the group consisting of naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, and phenyl.
claim 5
7. The method of , wherein the one or more additional heteroatom(s) in the 5-7 membered saturated or unsaturated heterocyclic ring is NH or NR1.
claim 5
8. The method of , wherein the heterocyclic ester or amide is a compound of formula II
claim 1
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A, B and C are independently CH2, O, S, SO, SO2, NH, or NR1;
R1 is C1-C5 straight or branched chain alkyl or C2-C5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n and C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
n is 1 or 2;
R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C1-C8 cycloalkyl, C5-C7 cycloalkenyl or Ar1; and
Ar1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 , alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
9. The method of , wherein:
claim 8
A is CH2;
B is CH2 or S;
C is CH2 or NH;
R1 is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl; and
R2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, and tert-butyl.
10. The method of , wherein:
claim 9
S is CH
C is NH; and
R1 is 3-phenylpropyl.
11. The method of , wherein:
claim 9
B is S; and
C is CH2.
12. The method of , wherein the compound is selected from the group consisting of: 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate;
claim 8
3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate; and
pharmaceutically acceptable salts, esters, and solvates thereof.
13. The method of , wherein the heterocyclic ester or amide is a compound of formula III
claim 1
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A, B, C and D are independently CH2, O, S, SO, SO2, NH, or NR1;
R1 is C1-C5 straight or branched chain alkyl or C2-C5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (AR1)n and C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
n is 1 or 2;
R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, or Ar1; and
Ar1is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C1-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
14. The method of , wherein:
claim 13
A is CH2;
B is CH2;
C is S, O, or NH;
D is CH2;
R1 is selected from the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl; and
R2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5- trimethoxyphenyl.
15. The compound of , wherein:
claim 14
C is NH; and
R2 is 1,1-dimethylpropyl or phenyl.
16. The method of , wherein the heterocyclic ester or amide is a compound of formula IV
claim 1
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
V is C, N, or S;
A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar3l wherein R is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy; phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamirnno, aminoalkyl, aminocarboxyl and Ar4;
Ar3 and Ar4 are independenrly an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and
R1, R2, W, X, Y, and Z are as defined in above.
claim 5
17. A pharmaceutical composition which comprises:
(i) an effective amount of a heterocyclic ester or amide for treating alopecia or promoting hair growth in an animal; and
(ii) a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of , wherein the heterocyclic ester or amide is non-immunosuppressive.
claim 17
19. The pharmaceutical composition of , wherein the heterocyclic ester or amide has an affinity for an FKBP-type immunophilin.
claim 17
20. The pharmaceutical composition of , wherein the FKBP-type immunophilin is FKBP-12.
claim 19
21. The pharmaceutical composition of , wherein the heterocyclic ester or amide is a compound of formula I
claim 17
or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:
A and B, together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO2, N, NH, or NR1 heteroatom;
X is O or S;
Z is O, NH or NR1;
W and Y are independently O, S, CH2, or H2;
R1 is C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n, C1-C6 cycloalkyl, C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with C3-C8 cycloalkyl, and Ar2;
n is 1 or 2;
R2 is either C1C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C1-C8 cycloalkyl, C5-C7 cycloalkenyl or Ar1, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C1-C4 straight or branched chain alkyl, C1-C4 straight or branched chain alkenyl, and hydroxy; and
Ar1 and Ar2 are independently an alicyclic or aromatic mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
22. The pharmaceutical composition of , wherein the mono- or bicyclic, carbo- or heterocyclic ring is selected from the group consisting of napthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, and phenyl.
claim 21
23. The pharmaceutical composition of , wherein the one or more additional heteroatom(s) in the 5-7 membered saturated or unsaturated heterocyclic ring is NH or NR1.
claim 21
24. The pharmaceutical composition of , wherein the heterocyclic ester or amide is a compound of formula II
claim 17
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A, B and C are independently CH2, O, S, SO, SO2, NH, or NR1;
R1 is C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n and C1-C6 straight or branched chain alkyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
n is 1 or 2;
R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar1; and
Ar1 is a an alicyclic or aromatic, mono, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting or halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C1-C5 alkenyloxy, phenoxy, benzyloxy, and amino, wherein the individual ring is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
25. The pharmaceutical composition of , wherein:
claim 24
A is OF2;
B is CH2 or S;
C is CH2 or NH;
R1 is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl; and
R2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, and tert-butyl.
26. The pharmaceutical composition of , wherein:
claim 25
B is CH2;
C is NH; and
R1 is 3-phenylpropyl.
27. The pharmaceutical composition of , wherein:
claim 25
B is S; and
C is CH2.
28. The pharmaceutical composition of , wherein the compound is selected from the group consisting of:
claim 24
3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate; and
pharmaceutically acceptable salts, esters, and solvates thereof.
29. The pharmaceutical composition of , wherein the heterocyclic ester or amide is a compound of formula III
claim 17
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A, B, C and D are independently CH2, O, S, SO, SO2, NH, or NR1;
R1 is C1-C5 straight or branched chain alkyl or C2-C5 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar1)n and C1-C6 straight or branched chain alkenyl or C2-C6 straight or branched chain alkenyl substituted with (Ar1)n;
n is 1 or 2;
R2 is either C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar1; and
Ar1is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.
30. The pharmaceutical composition of , wherein:
claim 29
A is C;
B is CH3;
C is S, O or NH;
D is CH2;
R, is selected the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl; and
R2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5-trimethoxyphenyl.
31. The compound of , wherein:
claim 30
C is NH; and
R2 is 1,1-dimethylpropyl or phenyl.
32. The pharmaceutical composition of , wherein the heterocyclic ester or amide is a compound of formula IV
claim 17
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
V is C, N, or S;
A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R is either C1-C9 straight or branched chain alkyl, C1-C9 straight or branched chain alkenyl, C1-C9 cycloalkyl, C5-C7 cycloalkenyl, or Ar3, wherein R is substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1-C6 straight or branched chain alkyl, C2-C5 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar4;
Ar3 and Ar4 are independently an alicyclic or aromatic mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and
R1, R2, W, X, Y, and Z are as defined in above.
claim 21
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/879,888 US20010041733A1 (en) | 1998-06-03 | 2001-06-14 | Heterocyclic ester and amide hair growth compositions and uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/089,377 US6274617B1 (en) | 1998-06-03 | 1998-06-03 | Heterocyclic ester and amide hair growth compositions and uses |
US09/879,888 US20010041733A1 (en) | 1998-06-03 | 2001-06-14 | Heterocyclic ester and amide hair growth compositions and uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/089,377 Division US6274617B1 (en) | 1998-06-03 | 1998-06-03 | Heterocyclic ester and amide hair growth compositions and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010041733A1 true US20010041733A1 (en) | 2001-11-15 |
Family
ID=22217329
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/089,377 Expired - Fee Related US6274617B1 (en) | 1998-06-03 | 1998-06-03 | Heterocyclic ester and amide hair growth compositions and uses |
US09/879,888 Abandoned US20010041733A1 (en) | 1998-06-03 | 2001-06-14 | Heterocyclic ester and amide hair growth compositions and uses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/089,377 Expired - Fee Related US6274617B1 (en) | 1998-06-03 | 1998-06-03 | Heterocyclic ester and amide hair growth compositions and uses |
Country Status (6)
Country | Link |
---|---|
US (2) | US6274617B1 (en) |
EP (1) | EP1085853A1 (en) |
JP (1) | JP2002516843A (en) |
AU (1) | AU770459B2 (en) |
CA (1) | CA2334204A1 (en) |
WO (1) | WO1999062487A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
US20050059693A1 (en) * | 1997-06-04 | 2005-03-17 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US9085555B2 (en) | 2011-01-04 | 2015-07-21 | Novartis Ag | Complement pathway modulators and uses thereof |
US9388199B2 (en) | 2012-06-28 | 2016-07-12 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9464081B2 (en) | 2012-06-28 | 2016-10-11 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9468661B2 (en) | 2012-06-28 | 2016-10-18 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9487483B2 (en) | 2012-06-28 | 2016-11-08 | Novartis Ag | Complement pathway modulators and uses thereof |
US9550755B2 (en) | 2012-07-12 | 2017-01-24 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2017027564A1 (en) * | 2015-08-13 | 2017-02-16 | River Town Therapeutics, Inc. | Compositions and methods for treating alopecia |
US9815819B2 (en) | 2012-06-28 | 2017-11-14 | Novartis Ag | Complement pathway modulators and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337340B1 (en) * | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
CN1240691C (en) * | 2001-12-06 | 2006-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | Substituted penta azacylo compounds and their use for preventing and treating nervous retrogression disease |
Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310461A (en) * | 1980-06-23 | 1982-01-12 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4374829A (en) * | 1978-12-11 | 1983-02-22 | Merck & Co., Inc. | Aminoacid derivatives as antihypertensives |
US4390695A (en) * | 1980-06-23 | 1983-06-28 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4438031A (en) * | 1982-02-24 | 1984-03-20 | American Home Products Corporation | N-(Alkylsulfonyl)-L-proline amide and N-(alkylsulfonyl)-2-carboxylic acid amide-indoline derivatives |
US4531964A (en) * | 1982-09-13 | 1985-07-30 | Nippon Kayaku Kabushiki Kaisha | Heterocyclic compound and a herbicidal composition containing said compound |
US4574079A (en) * | 1983-05-27 | 1986-03-04 | Gavras Haralambos P | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
US4578474A (en) * | 1980-06-23 | 1986-03-25 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4593102A (en) * | 1984-04-10 | 1986-06-03 | A. H. Robins Company, Inc. | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
US4808573A (en) * | 1980-10-23 | 1989-02-28 | Schering Corporation | Carboxyalkyl dipeptides and anti-hypertensive use thereof |
US4818749A (en) * | 1980-10-23 | 1989-04-04 | Schering Corporation | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5147877A (en) * | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5284840A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkylidene macrolides having immunosuppressive activity |
US5284826A (en) * | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
US5294603A (en) * | 1980-09-12 | 1994-03-15 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions containing didemnins |
US5319098A (en) * | 1993-05-18 | 1994-06-07 | Celgene Corporation | Process for the stereoselective preparation of L-alanyl-L-proline |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US5359138A (en) * | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
US5385918A (en) * | 1993-02-09 | 1995-01-31 | Miles Inc. | Aminomethylene-peptides as immunosuppressants |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5414083A (en) * | 1993-01-22 | 1995-05-09 | Chemie Linz Gesellschaft M.B.H. | Method for the production of N-cyclic and N,N'-dicyclic ureas and their use as chemical solvents |
US5447915A (en) * | 1990-02-28 | 1995-09-05 | President And Fellows Of Harvard College | Terminally blocked antiviral peptides |
US5457111A (en) * | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5470878A (en) * | 1993-03-31 | 1995-11-28 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
US5472687A (en) * | 1985-07-18 | 1995-12-05 | Proctor; Peter H. | Topical pyridine N-oxides |
US5506228A (en) * | 1995-02-23 | 1996-04-09 | Merck & Co., Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
US5532248A (en) * | 1991-05-13 | 1996-07-02 | Merck Co., Inc. | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity |
US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5620971A (en) * | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
US5714510A (en) * | 1985-07-18 | 1998-02-03 | Proctor; Peter H. | Topical proxyl composition and method |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6187796B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
US6187784B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6294551B1 (en) * | 1996-12-31 | 2001-09-25 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2505114C3 (en) | 1975-02-07 | 1979-06-13 | Valentin Dr.Med. Koehler | Scalp care products |
GR75019B (en) | 1980-09-17 | 1984-07-12 | Univ Miami | |
ZA826022B (en) | 1981-08-21 | 1983-08-31 | Univ Miami | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides |
EP0088350B1 (en) | 1982-03-08 | 1985-02-20 | Schering Corporation | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
DE3508251A1 (en) | 1985-03-08 | 1986-09-11 | Merck Patent Gmbh, 6100 Darmstadt | Dipeptides |
CN86101850A (en) | 1985-03-22 | 1987-02-04 | 森得克斯(美国)有限公司 | N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides |
WO1988000040A1 (en) | 1986-07-02 | 1988-01-14 | American Health Products Corporation | Topical hair growing composition and kit |
DE3774975D1 (en) | 1986-09-10 | 1992-01-16 | Syntex Inc | SELECTIVE AMIDINATION OF DIAMINES. |
IT1206078B (en) | 1987-06-03 | 1989-04-14 | Polifarma Spa | PROCEDURE FOR THE PRODUCTION OF 3-INDOLPIRUVIC ACID AND ITS DERIVATIVES THEIR PHARMACEUTICAL USE |
WO1989006234A1 (en) | 1987-12-28 | 1989-07-13 | Bazzano Gail S | N,n-substituted amines and use thereof in hair growth promotion |
US5187156A (en) | 1988-03-16 | 1993-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same |
IL90872A0 (en) | 1988-07-08 | 1990-02-09 | Smithkline Beckman Corp | Retroviral protease binding peptides |
DE3931051A1 (en) | 1988-09-22 | 1990-03-29 | Hoechst Ag | New herbicidal amine salts of herbicidal acids |
EP0378318A1 (en) | 1989-01-11 | 1990-07-18 | Merck & Co. Inc. | Process for synthesis of FK-506 and tricarbonyl intermediates |
US5162500A (en) | 1989-04-15 | 1992-11-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
US5164525A (en) | 1989-06-30 | 1992-11-17 | Merck & Co., Inc. | Synthetic process for fk-506 type macrolide intermediates |
NZ234883A (en) | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
FR2651122B1 (en) | 1989-08-29 | 1994-10-28 | Oreal | COMPOSITIONS FOR USE IN BRAKING HAIR LOSS AND INDUCING AND STIMULATING THEIR GROWTH, CONTAINING 2-AMINO PYRIMIDINE OXIDE-3 DERIVATIVES AND NEW AMINO-2 PYRIMIDINE OXIDE-3 DERIVATIVES. |
GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
KR0159766B1 (en) | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | Hair revitalizing agent |
US5097209A (en) | 1990-02-21 | 1992-03-17 | The Torrington Company | Magnetic encoder and sensor system for internal combustion engines |
JPH04211648A (en) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | Keto-acid amide derivative |
DE4015255A1 (en) | 1990-05-12 | 1991-11-14 | Hoechst Ag | OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE |
DE69030923T2 (en) * | 1990-08-14 | 1998-01-29 | Kenneth M Hallam | Hair restorer |
EP0546115A1 (en) | 1990-08-24 | 1993-06-16 | The Upjohn Company | Peptides containing amino-polyols as transition-state mimics |
WO1992004370A1 (en) | 1990-08-29 | 1992-03-19 | Vertex Pharmaceuticals Incorporated | Modified di- and tripeptidyl immunosuppressive compounds |
GB2247456A (en) | 1990-09-03 | 1992-03-04 | Fujisawa Pharmaceutical Co | Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same |
JPH04149166A (en) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | Novel keto acid amide derivative |
FR2671082B1 (en) | 1990-12-28 | 1993-04-16 | Oreal | MULTI-COMPONENT AGENT OR KIT FOR PREPARING THE SULFO-CONJUGATED FORM OF PYRIMIDINO- OR TRIAZINO-N-OXIDE COMPOUNDS AND METHOD FOR IMPLEMENTING SAME. |
WO1992016501A1 (en) | 1991-03-20 | 1992-10-01 | Vertex Pharmaceuticals Incorporated | Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease |
IT1245712B (en) | 1991-04-09 | 1994-10-14 | Boehringer Mannheim Italia | USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION |
HUT70259A (en) | 1991-05-08 | 1995-09-28 | Vertex Pharma | Rfkbp: a novel isomerase and papamycin/fk506 binding protein |
ATE183178T1 (en) | 1991-05-09 | 1999-08-15 | Vertex Pharma | NEW IMMUNOSUPRESSIVE COMPOUNDS |
MX9202466A (en) | 1991-05-24 | 1994-06-30 | Vertex Pharma | NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS. |
FR2677884B1 (en) | 1991-06-20 | 1993-07-09 | Oreal | COMPOSITION FOR BRAKING HAIR LOSS BASED ON TRISUBSTITUTED N-OXIDE PYRIMIDINES OR THEIR SULFOCONJUGAL DERIVATIVES, NOVEL PYRIMIDINE N-OXIDE COMPOUNDS OR THEIR SULFOCONJUGAL DERIVATIVES. |
JPH05178824A (en) | 1991-08-05 | 1993-07-20 | Takeda Chem Ind Ltd | Asparagine derivative and its use |
AU2803692A (en) | 1991-10-11 | 1993-05-03 | Vertex Pharmaceuticals Incorporated | Isolation of an mr 52,000 fk506 binding protein and molecular cloning of a corresponding human cdna |
WO1993013066A1 (en) | 1991-12-20 | 1993-07-08 | Syntex (U.S.A.) Inc. | Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors |
GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
WO1993014762A1 (en) | 1992-01-27 | 1993-08-05 | Merck & Co., Inc. | 17β-HYDROXYBENZOYL-4-AZA-5α-ANDROST-1-EN-3-ONES USEFUL TO TREAT BALDNESS |
WO1993018736A1 (en) | 1992-03-19 | 1993-09-30 | Armand Pardo | Cosmetic hair care compositions for treating hair loss |
CA2091194A1 (en) | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
WO1993023548A2 (en) | 1992-05-20 | 1993-11-25 | Vertex Pharmaceuticals Incorporated | METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF |
IT1254373B (en) | 1992-05-29 | 1995-09-14 | HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR EMPLOYE THERAPEUTIC. | |
US5334719A (en) | 1992-06-17 | 1994-08-02 | Merck Frosst Canada, Inc. | Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis |
GB9216329D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives |
IS2334B (en) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl protease inhibitor of a new class of sulfonamides |
NZ314207A (en) | 1992-09-28 | 2000-12-22 | Vertex Pharma | 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers |
AU5748194A (en) | 1992-12-11 | 1994-07-04 | Vertex Pharmaceuticals Incorporated | Mannitol derivatives and their use as inhibitors of aspartyl protease |
JPH09503645A (en) | 1993-07-16 | 1997-04-15 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ | Controlled apoptosis |
IT1270882B (en) | 1993-10-05 | 1997-05-13 | Isagro Srl | FUNGICIDE-BASED OLIGOPEPTIDES |
JPH09504553A (en) * | 1993-11-04 | 1997-05-06 | メルク エンド カンパニー インコーポレーテッド | 7-Substituted-4-aza-steroid derivatives as 5α-reductase inhibitors |
EP0823419A3 (en) | 1996-08-09 | 2000-08-16 | Takeda Chemical Industries, Ltd. | Dimethylpropanediol compounds |
US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
-
1998
- 1998-06-03 AU AU77170/98A patent/AU770459B2/en not_active Ceased
- 1998-06-03 EP EP98925156A patent/EP1085853A1/en not_active Withdrawn
- 1998-06-03 JP JP2000551743A patent/JP2002516843A/en active Pending
- 1998-06-03 WO PCT/US1998/011250 patent/WO1999062487A1/en active IP Right Grant
- 1998-06-03 CA CA002334204A patent/CA2334204A1/en not_active Abandoned
- 1998-06-03 US US09/089,377 patent/US6274617B1/en not_active Expired - Fee Related
-
2001
- 2001-06-14 US US09/879,888 patent/US20010041733A1/en not_active Abandoned
Patent Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374829A (en) * | 1978-12-11 | 1983-02-22 | Merck & Co., Inc. | Aminoacid derivatives as antihypertensives |
US4578474A (en) * | 1980-06-23 | 1986-03-25 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4390695A (en) * | 1980-06-23 | 1983-06-28 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US4310461A (en) * | 1980-06-23 | 1982-01-12 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
US5294603A (en) * | 1980-09-12 | 1994-03-15 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions containing didemnins |
US4808573A (en) * | 1980-10-23 | 1989-02-28 | Schering Corporation | Carboxyalkyl dipeptides and anti-hypertensive use thereof |
US4818749A (en) * | 1980-10-23 | 1989-04-04 | Schering Corporation | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure |
US4438031A (en) * | 1982-02-24 | 1984-03-20 | American Home Products Corporation | N-(Alkylsulfonyl)-L-proline amide and N-(alkylsulfonyl)-2-carboxylic acid amide-indoline derivatives |
US4531964A (en) * | 1982-09-13 | 1985-07-30 | Nippon Kayaku Kabushiki Kaisha | Heterocyclic compound and a herbicidal composition containing said compound |
US4574079A (en) * | 1983-05-27 | 1986-03-04 | Gavras Haralambos P | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
US4593102A (en) * | 1984-04-10 | 1986-06-03 | A. H. Robins Company, Inc. | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
US5472687A (en) * | 1985-07-18 | 1995-12-05 | Proctor; Peter H. | Topical pyridine N-oxides |
US5714510A (en) * | 1985-07-18 | 1998-02-03 | Proctor; Peter H. | Topical proxyl composition and method |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5359138A (en) * | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
US5284826A (en) * | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
US5447915A (en) * | 1990-02-28 | 1995-09-05 | President And Fellows Of Harvard College | Terminally blocked antiviral peptides |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5516797A (en) * | 1990-07-02 | 1996-05-14 | Vertex Pharmaceuticals, Incorporated | Immunosuppressive compounds |
US5330993A (en) * | 1990-07-02 | 1994-07-19 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
US5147877A (en) * | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
US5620971A (en) * | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
US5532248A (en) * | 1991-05-13 | 1996-07-02 | Merck Co., Inc. | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5457111A (en) * | 1991-09-05 | 1995-10-10 | Abbott Laboratories | Macrocyclic immunomodulators |
US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5284840A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkylidene macrolides having immunosuppressive activity |
US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5414083A (en) * | 1993-01-22 | 1995-05-09 | Chemie Linz Gesellschaft M.B.H. | Method for the production of N-cyclic and N,N'-dicyclic ureas and their use as chemical solvents |
US5385918A (en) * | 1993-02-09 | 1995-01-31 | Miles Inc. | Aminomethylene-peptides as immunosuppressants |
US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
US5470878A (en) * | 1993-03-31 | 1995-11-28 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
US5319098A (en) * | 1993-05-18 | 1994-06-07 | Celgene Corporation | Process for the stereoselective preparation of L-alanyl-L-proline |
US5424454A (en) * | 1993-05-18 | 1995-06-13 | Celgene Corporation | Process for the stereoselective preparation of l-alanyl-l-proline |
US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
US5506228A (en) * | 1995-02-23 | 1996-04-09 | Merck & Co., Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US6218544B1 (en) * | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic esters and amides |
US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US6200972B1 (en) * | 1996-09-25 | 2001-03-13 | Gpi Nil Holdings, Inc. | Heterocyclic esters and amides |
US6294551B1 (en) * | 1996-12-31 | 2001-09-25 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
US6004993A (en) * | 1997-06-04 | 1999-12-21 | Gpi Nil Holdings, Inc. | N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses |
US6177455B1 (en) * | 1997-06-04 | 2001-01-23 | Gpi Nil Holdings, Inc. | Pyrrolidine derivative hair growth compositions and uses |
US6239164B1 (en) * | 1997-06-04 | 2001-05-29 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate and pyrrolidine amide hair revitalizing agents |
US6187806B1 (en) * | 1997-06-04 | 2001-02-13 | Gpi Nil Holdings | N-linked sulfone of heterocyclic thioester hair growth compositions and uses |
US6191125B1 (en) * | 1997-06-04 | 2001-02-20 | Gpi Nil Holdings, Inc. | Small molecule pipecolic acid derivative hair growth compositions and uses |
US6194440B1 (en) * | 1997-06-04 | 2001-02-27 | Gpi Nil Holdings, Inc. | Small molecule carbamate or urea hair growth compositions and uses |
US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6187784B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6187796B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198250A1 (en) * | 1997-06-04 | 2002-12-26 | Steiner Joseph P. | Pyrrolidine derivative hair growth compositions and uses |
US20050059693A1 (en) * | 1997-06-04 | 2005-03-17 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
US6943187B2 (en) | 1997-06-04 | 2005-09-13 | Gpi Nil Holdings, Inc. | Pyrrolidine derivative hair growth compositions and uses |
US9085555B2 (en) | 2011-01-04 | 2015-07-21 | Novartis Ag | Complement pathway modulators and uses thereof |
US9388199B2 (en) | 2012-06-28 | 2016-07-12 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9464081B2 (en) | 2012-06-28 | 2016-10-11 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9468661B2 (en) | 2012-06-28 | 2016-10-18 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
US9487483B2 (en) | 2012-06-28 | 2016-11-08 | Novartis Ag | Complement pathway modulators and uses thereof |
US9815819B2 (en) | 2012-06-28 | 2017-11-14 | Novartis Ag | Complement pathway modulators and uses thereof |
US9550755B2 (en) | 2012-07-12 | 2017-01-24 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2017027564A1 (en) * | 2015-08-13 | 2017-02-16 | River Town Therapeutics, Inc. | Compositions and methods for treating alopecia |
Also Published As
Publication number | Publication date |
---|---|
WO1999062487A1 (en) | 1999-12-09 |
AU770459B2 (en) | 2004-02-19 |
AU7717098A (en) | 1999-12-20 |
US6274617B1 (en) | 2001-08-14 |
JP2002516843A (en) | 2002-06-11 |
EP1085853A1 (en) | 2001-03-28 |
CA2334204A1 (en) | 1999-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6191125B1 (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
US6274617B1 (en) | Heterocyclic ester and amide hair growth compositions and uses | |
US6187784B1 (en) | Pipecolic acid derivative hair growth compositions and uses | |
US6172087B1 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
AU764032B2 (en) | Small molecule carbamate or urea hair growth compositions and uses | |
AU761737B2 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
US6187796B1 (en) | Sulfone hair growth compositions and uses | |
EP1083874B1 (en) | Use of a compound for the preparation of a medicament for treating alopecia or promoting hair growth in an animal | |
US20010049381A1 (en) | Pyrrolidine derivative hair growth compositions and uses | |
US6271244B1 (en) | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses | |
AU761083B2 (en) | Pipecolic acid derivative hair growth compositions and uses | |
US6274602B1 (en) | Heterocyclic thioester and ketone hair growth compositions and uses | |
EP1083873B1 (en) | Heterocyclic thioester and ketone hair growth compositions and uses | |
US20020010205A1 (en) | N-linked sulfone of heterocyclic thioester hair growth compositions and uses | |
US20020065297A1 (en) | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses | |
MXPA00011912A (en) | Heterocyclic ester and amide hair growth compositions and uses | |
MXPA00011850A (en) | Small molecule pipecolic acid derivative hair growth compositions and uses | |
AU8252898A (en) | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |
|
AS | Assignment |
Owner name: GLIAMED, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GPI IP, LLC, D/B/A MGL PHARMA;REEL/FRAME:019477/0568 Effective date: 20070405 |